Patents by Inventor Joseph A. Fix

Joseph A. Fix has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10402950
    Abstract: Methods for quantifying pupil swim are disclosed in order to compensate for the same. A target image, in one embodiment, is displayed on a display of a head mounted display (HMD). Images of the target image are captured from a plurality of positions relative to an optical axis of an optics block of the HMD at an exit pupil of the HMD. The target image includes features and differences between observed locations of the features and their expected locations absent the optics block are determined. From these differences, a wavefront of the optics block is reconstructed and distortion corrections for the optics block are generated using the wavefront. The distortion corrections, when applied to a virtual scene, add pre-distortion that is canceled by the optical imperfections of the optics block as light of the virtual scene with the pre-distortion passes through the optics block.
    Type: Grant
    Filed: November 15, 2017
    Date of Patent: September 3, 2019
    Assignee: Facebook Technologies, LLC
    Inventors: Ying Geng, Stephen James McNally, Brett Joseph Bryars, Scott Charles McEldowney, Alexander Jobe Fix, Douglas Robert Lanman
  • Publication number: 20180185356
    Abstract: A method of treating diarrhea in a patient includes administering a dose of 2.0-7.0 mg of cetirizine and 3.0-15.0 mg of famotidine.
    Type: Application
    Filed: December 22, 2017
    Publication date: July 5, 2018
    Inventors: Reed B. Hogan, II, Joseph A. Fix
  • Patent number: 10010529
    Abstract: The present invention provides extended release pharmaceutical formulations of valsartan with controlled impurity levels. Particularly, the present invention provides extended release valsartan formulation which is substantially free of valsartan R-isomer impurity.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: July 3, 2018
    Assignees: Ezra Pharma LLC, Rubicon Research Private Limited
    Inventors: Joseph A. Fix, Shirish A. Shah, Pratibha S. Pilgaonkar, Anilkumar S. Gandhi
  • Publication number: 20170326065
    Abstract: The present invention relates to methods for treatment of cardiovascular conditions selected from high blood pressure, heart failure, or heart attack. The present invention further relates to a method of treating cardiovascular conditions comprising orally administering once a day to a human subject in need thereof the compound valsartan in an extended release dosage form, wherein the ratio of mean plasma concentration of valsartan provided by the extended release dosage form to the mean plasma concentration of valsartan provided by an immediate release dosage form of valsartan over 8 hour to 24 hour period after administration is greater than 1 in a single dose human pharmacokinetic study.
    Type: Application
    Filed: May 13, 2016
    Publication date: November 16, 2017
    Applicants: Ezra Pharma LLC, Rubicon Research Private Limited
    Inventors: Joseph A. Fix, Shirish A. Shah, Pratibha S. Pilgaonkar, Anilkumar S. Gandhi
  • Publication number: 20170326066
    Abstract: The present invention relates to methods and composition for treatment of hypertension. Particularly the present invention provides a method of treating hypertension comprising orally administering once a day to a human patient in need thereof the compound valsartan in an extended release dosage form, wherein said extended release valsartan dosage form reduces mean systolic and diastolic blood pressure in a patient during a time period of about 20 hours to about 24 hours after administration to a greater extent than an immediate release formulation of valsartan.
    Type: Application
    Filed: May 13, 2016
    Publication date: November 16, 2017
    Applicants: Ezra Pharma LLC, Rubicon Research Private Limited
    Inventors: Joseph A. Fix, Shirish A. Shah, Pratibha S. Pilgaonkar, Anilkumar S. Gandhi
  • Publication number: 20170290805
    Abstract: The present invention provides extended release pharmaceutical formulations of valsartan with controlled impurity levels. Particularly, the present invention provides extended release valsartan formulation which is substantially free of valsartan R-isomer impurity.
    Type: Application
    Filed: June 26, 2017
    Publication date: October 12, 2017
    Applicants: Ezra Pharma LLC, Rubicon Research Private Limited
    Inventors: Joseph A. Fix, Shirish A. Shah, Pratibha S. Pilgaonkar, Anilkumar S. Gandhi
  • Publication number: 20170273946
    Abstract: The present invention relates to coated extended release pharmaceutical formulations of valsartan comprising a core comprising valsartan and at least one coating layer over the core. The present invention further relates to extended release pharmaceutical formulations comprising (a) a core comprising valsartan and at least one hydrophilic swelling polymer and (b) at least one coating layer over the core wherein the coating layer in contact with the core is applied from an organic solvent based system.
    Type: Application
    Filed: June 12, 2017
    Publication date: September 28, 2017
    Applicants: Ezra Pharma LLC, Rubicon Research Private Limited
    Inventors: Joseph A. Fix, Shirish A. Shah, Pratibha S. Pilgaonkar, Anilkumar S. Gandhi
  • Patent number: 9687475
    Abstract: The present invention provides extended release pharmaceutical formulations of valsartan with controlled impurity levels. Particularly, the present invention provides extended release valsartan formulation which is substantially free of valsartan R-isomer impurity.
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: June 27, 2017
    Assignees: Ezra Pharma LLC, Rubicon Research Private Limited
    Inventors: Joseph A. Fix, Shirish A. Shah, Pratibha S. Pilgaonkar, Anilkumar S. Gandhi
  • Patent number: 9675585
    Abstract: The present invention relates to coated extended release pharmaceutical formulations of valsartan comprising a core comprising valsartan and at least one coating layer over the core. The present invention further relates to extended release pharmaceutical formulations comprising (a) a core comprising valsartan and at least one hydrophilic swelling polymer and (b) at least one coating layer over the core wherein the coating layer in contact with the core is applied from an organic solvent based system.
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: June 13, 2017
    Assignees: Ezra Pharma, Rubicon Research Private Limited
    Inventors: Joseph A. Fix, Shirish A. Shah, Pratibha S. Pilgaonkar, Anilkumar S. Gandhi
  • Publication number: 20040105903
    Abstract: The invention is directed to novel tablets comprising isoflavone-containing plant extract and water-insoluble polysaccharides, and methods of manufacturing them.
    Type: Application
    Filed: November 14, 2003
    Publication date: June 3, 2004
    Applicants: Johnson & Johnson Consumer Companies, Inc., Indena, S.P.A.
    Inventors: Min Michael He, Fang-Yu Liu, Joseph A. Fix, Martin Link, Maria L. Kang, Ezio Bombardelli
  • Publication number: 20040091528
    Abstract: This invention relates to novel oral sustained-release formulations for delivery of an active agent (e.g., a drug), especially a highly water soluble drug. More particularly, this invention relates to novel formulations comprising a micelle-forming drug having a charge and at least one polymer having an opposite charge. Methods of using the novel formulations are also provided.
    Type: Application
    Filed: November 12, 2002
    Publication date: May 13, 2004
    Applicants: Yamanouchi Pharma Technologies, Inc., Yamanouchi Pharmaceutical Co. Ltd.
    Inventors: Victoria Rogers, Philippe J.M. Dor, Joseph A. Fix, Hiroyuki Kojima, Kazuhiro Sako
  • Patent number: 6669956
    Abstract: The invention is directed to novel tablets comprising isoflavone-containing plant extract and water-insoluble polysaccharides, and methods of manufacturing them.
    Type: Grant
    Filed: May 23, 2002
    Date of Patent: December 30, 2003
    Assignees: Indena S.p.A., Johnson & Johnson Consumer Companies, Inc.
    Inventors: Min Michael He, Fang-Yu Liu, Joseph A. Fix, Martin Link, Maria L. Kang, Ezio Bombardelli
  • Publication number: 20030129226
    Abstract: The invention provides for novel compressed tablets capable of rapidly disintegrating in aqueous solutions, comprising at least one non-saccharide water soluble polymer, which are free of organic solvent residues, and methods of making such pharmaceuticals.
    Type: Application
    Filed: October 9, 2002
    Publication date: July 10, 2003
    Applicant: YAMANOUCHI PHARMA TECHNOLOGIES, INC.
    Inventors: Fang-yu Liu, Min Michael He, Janaki Ram Nyshadham, Kuldeepak Sharma, James Shunnan Chu, Joseph A. Fix
  • Publication number: 20030108602
    Abstract: The invention provides a tablet and methods for making the tablet comprising a gel-forming material and at least one particle comprising an active agent in contact with a coating material to modify release of the active agent.
    Type: Application
    Filed: July 8, 2002
    Publication date: June 12, 2003
    Applicant: Yamanouchi Pharma Technologies, Inc.
    Inventors: James Shunnan Chu, Yisong Yang, Joseph A. Fix
  • Publication number: 20020182275
    Abstract: The invention is directed to novel tablets comprising isoflavone-containing plant extract and water-insoluble polysaccharides, and methods of manufacturing them.
    Type: Application
    Filed: May 23, 2002
    Publication date: December 5, 2002
    Applicant: Johnson & Johnson Consumer Companies, Inc.
    Inventors: Min Michael He, Fang-Yu Liu, Joseph A. Fix, Martin Link, Maria L. Kang, Ezio Bombardelli
  • Patent number: 6465009
    Abstract: The invention provides for novel compressed tablets capable of rapidly disintegrating in aqueous solutions, comprising at least one non-saccharide water soluble polymer, which are free of organic solvent residues, and methods of making such pharmaceuticals.
    Type: Grant
    Filed: March 18, 1998
    Date of Patent: October 15, 2002
    Assignee: Yamanouchi Pharmaceutical Co., Ltd.
    Inventors: Fang-yu Liu, Min Michael He, Janaki Ram Nyshadham, Kuldeepak Sharma, James Shunnan Chu, Joseph A. Fix
  • Patent number: 6419954
    Abstract: The invention provides a tablet and methods for making the tablet comprising a gel-forming material and at least one particle comprising an active agent in contact with a coating material to modify release of the active agent.
    Type: Grant
    Filed: May 19, 2000
    Date of Patent: July 16, 2002
    Assignee: Yamanouchi Pharmaceutical Co., Ltd.
    Inventors: James S. Chu, Yisong Yang, Joseph A. Fix
  • Patent number: 6413546
    Abstract: The invention is directed to novel tablets comprising isoflavone-containing plant extract and water-insoluble polysaccharides, and methods of manufacturing them.
    Type: Grant
    Filed: March 18, 1999
    Date of Patent: July 2, 2002
    Assignees: Indena, S.p.A., Johnson & Johnson Consumer Companies, Inc.
    Inventors: Min Michael He, Fang-Yu Liu, Joseph A. Fix, Martin Link, Maria L. Kang, Ezio Bombardelli
  • Patent number: 6111238
    Abstract: An automated microwave sample digestion system is disclosed in which a focused microwave digestion system is operated under computer control in association with a computer controlled robotic positioning system such that sample tubes containing samples to be digested are loaded and unloaded into and out from the cooking cavities of the microwave digestion oven in a preprogrammed manner in order to both increase the efficiency of the processing of samples as well as to produce consistent operating conditions for each sample being digested. An additional pump and syringe line is provided for both washing the tube condenser utilized during the digestion process as well as for diluting the digested sample.
    Type: Grant
    Filed: March 4, 1998
    Date of Patent: August 29, 2000
    Assignee: R. J. Reynolds Tobacco Company
    Inventors: Robert Joseph Fix, Sr., Jannell Mills Rowe, Samuel Mark DeBusk, Bain Clifford McConnell, John Larkin Nelson, Nancy Carol Huettel
  • Patent number: 4973579
    Abstract: Choline ester salts are used as drug absorption enhancing agents for orally and rectally administered drugs.
    Type: Grant
    Filed: February 16, 1989
    Date of Patent: November 27, 1990
    Assignee: Merck & Co., Inc.
    Inventors: Jose Alexander, Joseph A. Fix